The Egyptian Drug Authority (EDA) participated in the Africa Regional Chapter Meeting of the United States Pharmacopeia (USP), held in Johannesburg from 27 to 29 April 2026. This participation comes as part of the Authority’s ongoing commitment to strengthening its regional role and exchanging expertise with leading regulatory bodies across Africa.
Representing the EDA at the meeting were Dr. Tamer Elhossieny, Vice Chairman of the Egyptian Drug Authority, and Dr. Asmaa Fouad, Head of the Central Administration of Biologicals, Innovative Products, and Clinical Studies.
During the event, Dr. Tamer Elhossieny participated in a panel discussion titled: “Meeting of African Reference Regulatory Authorities Achieving Maturity Level 3 (ML3),” which brought together representatives from several leading regulatory agencies across Africa.
The session highlighted the importance of attaining Maturity Level 3 (ML3) as an indicator of a well-established regulatory system capable of performing its core functions efficiently and sustainably. It also addressed ways to strengthen regulatory integration and coordination among African authorities, supporting a more robust and effective pharmaceutical system across the continent.
Dr. Tamer Elhossieny presented the Egyptian Drug Authority’s experience in advancing its regulatory system and enhancing operational efficiency, emphasizing the importance of knowledge exchange among African countries to support regional integration and achieve pharmaceutical security.
Dr. Asmaa Fouad also participated virtually in a session titled: “Latest Regulatory Frameworks Adopted by the Egyptian Drug Authority to Ensure the Quality and Efficacy of Biosimilars.” She discussed the regulatory challenges associated with the evaluation of biological and biosimilar products and reviewed the Authority’s efforts to develop regulatory frameworks and build technical capacity in line with the latest international standards.
This participation reflects the Egyptian Drug Authority’s ongoing commitment to strengthening international cooperation, supporting the development of regulatory capacities, and actively contributing to discussions on critical issues related to the quality, safety, and efficacy of pharmaceutical products—further reinforcing Egypt’s position as a leading regional hub in the pharmaceutical sector.